About The ASCR Network
The Adult Stem Cell Research (ASCR) Network is an Internet-based project of The Cell Therapy Foundation designed to be a well-maintained and reliable source of information for the public regarding adult stem cell research, as well as to be a community of practice and collaboration among fellow researchers. ASCR publishes the latest scientific news in the adult stem cell arena, identifies the leading researchers in the field, and locates key clinical trials; as well as connects the global community of adult stem cell researchers with one another.
Apceth Wins Approval for Trial with Engineered Adult Stem Cell Cancer Therapy
Cell therapies firm apceth has won regulatory clearance in Germany to start an open-label mulitcentre Phase I/II trial evaluating its genetically modified, autologous adult mesenchymal stem cell (MSC) therapy, Agenmestencel-T, in adult patients with advanced adenocarcinoma of the gastrointestinal tract.
Agenmestencel-T is generated from the patient’s own MSCs. The cells are harvested from the bone marrow, engineered to carry a cancer-targeting cytotoxic gene product based on a based on gamma-SIN-vector, and then readministered into the patient. Therapy is designed to be activated only at the tumor site, to increase local efficacy and reduce systemic toxicity.
Bioheart Announces Phase I ANGEL Trial Completed
SUNRISE, FL--(Marketwired - Jun 12, 2013) - Bioheart, Inc. (OTCQB: BHRT) announced today that they have successfully enrolled and treated all patients in the phase I ANGEL Trial. The trial, which is fully funded by Bioheart, is being conducted in Mexico at the Hospital Angeles with the Regenerative Medicine Institute (RMI). This phase I study will provide necessary safety and preliminary efficacy of adipose-derived stem cells in patients with congestive heart failure. Endpoints include safety, exercise capacity, quality of life, and ejection fraction at 3 months, 6 months and 12 months.
Kristin Comella, Bioheart's Chief Science Officer, said, "We were so excited to see brisk enrollment in the study. Once we collect preliminary safety and efficacy, we will expand the study into a Phase II trial."
SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product, SB623, in Patients with Traumatic Brain Injury
MOUNTAIN VIEW, Calif., June 10, 2013 /PRNewswire/ -- SanBio Inc., a California-based regenerative medicine company, announced today that the U.S. Food and Drug Administration has approved their Investigational New Drug application (IND) for the use of SB623, a novel allogeneic stem cell therapy product, in patients suffering from traumatic brain injuries (TBI's). This approval allows the company to proceed with a Phase 1/2a clinical trial testing the safety and feasibility of the therapy. The clinical trial is expected to be carried out at several major hospitals in the United States.
"This is the second clinical program for SanBio," said Keita Mori, SanBio's Chief Executive Officer, "we see this as a clear validation of our development program and a significant broadening of the therapeutic application of our lead product SB623 for the treatment of unaddressed chronic neurological deficits."
BrainStorm Treats 8th Patient in Phase IIa Trial; Completes Enrollment of Final 4 Patients
NEW YORK & PETACH TIKVAH, (Israel) – June 10, 2013 - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has successfully treated the eighth patient in its ongoing Phase IIa ALS clinical trial at the Hadassah Medical Center in Jerusalem, Israel, thus completing treatment of the second of three cohorts. Enrollment of the final group of four patients has also been completed, and the company expects to conclude treatment of these patients by the end of the third quarter of this year.
In this Phase IIa dose-escalating trial, currently underway at Hadassah under the direction of Principal Investigator Professor Dimitrios Karussis, 12 ALS patients are receiving combined intramuscular (IM) and intrathecal (IT) administration of NurOwn cells, in three cohorts, with increasing doses. The study participants will be monitored for six months following transplantation.
* Designates sites with available clinical trials.
- * Adult Stem Cell Laboratory, Medical College of Georgia
- * Feinberg Cardiovascular Research Institute - Northwestern University, Chicago, IL
- * Indiana Center for Vascular Biology and Medicine, Laboratories - Indianapolis, IN
- * Regenerative Medicine Institute, Mexico
- * Stem Cell Center at Texas Heart Institute - Houston, TX
- Adipose Stem Cell Center, University of Pittsburgh - Pittsburgh, PA
- Adipose Tissue Plasticity - Toulouse France
- Adult Stem Cell Laboratory - Seoul, South Korea
- Adult Stem Cell Research Ctr, Seoul National University - Seoul, South Korea
- The Cardiovascular Research Institute - Washington, DC
- Center for Cardiovascular Cell Therapy - Louisville, KY
- Division of Clinical Immunology and Transfusional Medicine - Stockholm, Sweden
- Excellion Biomedical Services - Petropolis, Rio de Janeiro
- Interdisciplinary Stem Cell Institute/UM Med - Miami, FL
- Institute of Cell and Molecular Science - London, England
- Kolonin Lab - Centre for Stem Cell Research - Houston, TX
- Laboratory for Stem Cell Injury - Charleston, SC
- LIT - Laboratory of Transplantation Immunobiology - Sao Paulo, Brazil
- Minneapolis Heart Institute Foundation - Minneapolis, MN
- Molecular Cardiology Laboratory - ThoraxCenter - Rotterdam, Netherlands
- National Centre for Adult Stem Cell Research at Griffith University - Nathan Queensland, Australia
- Naviaux Lab - The Mitochondrial and Metabolic Disease Center - San Diego, CA
- Oklahoma Center for Adult Stem Cell Research (OCASCR) - Oklahoma City, OK
- Penn Lab - Cleveland Clinic - Cleveland, OH
- Prantl Laboratory - Center for Adult Stem Cell Research - Regensburg, Germany
- Research & Development Unit - National Heart Centre, Singapore
- RhinoCyte™, Inc. - Louisville, KY
- Scandurro Research Laboratory - New Orleans, LA
- Simari Lab - Mayo Clinic - Rochester, MN
- Skeletal Tissue Engineering Group - Amsterdam
- Skeletal Research Center, Case Western Reserve University - Cleveland, OH
- Stem Cell Biology Laboratory, Pennington Biomedical Research Center - Baton Rouge, LA
- Stem Cell Biology and Cell Therapy Laboratory - Philadelphia, PA
- Stem Cell Research Center - Pittsburgh, PA
- Stem Cell Research Center - Taipei, Taiwan
- Yoder Laboratory - Indianapolis, IN
- Wake Forest Institute of Regenerative Medicine - Winston-Salem, NC